List of Biosimilars Companies in China - 12

Alphamab Oncology (Stock code: 9966.HK) is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment. With multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and we are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.

Bio-Thera Solutions is a clinical-stage pharmaceutical company focused on biologic therapeutics. Bio-Thera is developing a pipeline on innovative enhanced monoclonal antibodies and antibody-drug conjugates for the treatment of a broad range of cancers and other diseases as well as a pipeline of biosimilars in the autoimmune and oncology therapeutic areas. The company is headquartered in Guangzhou, China.

Founded in 2007, we are a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing, and commercial capabilities as well as strong partnerships with organizations globally, we have developed a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. As we focus on delivering vaccines for a healthier world, we remain steadfast in our dedication to both scientific innovation and equitable access.

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business. Fosun Pharma is patient-centered and clinical needs-oriented. The company continuously enriches its innovative product pipeline through independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma improves the research and clinical development capabilities of FIC (First-in-class) and BIC (Best-in-class) new drugs as well as accelerates the R&D and launch of innovative technologies and products. Fosun Pharma’s innovative products mainly covered core therapeutic areas such as tumors (solid tumors and hematologic tumors), immunology, central nervous system, and chronic diseases (liver disease/metabolism/kidney disease). Guided by the 4IN strategy (Innovation, Internationalization, Intelligentization, and Integration), Fosun Pharma will uphold the development model of “Innovation Transformation, Integrated Operation and Steady Growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global pharmaceutical and healthcare markets.

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions. Gan & Lee is committed to providing solutions to patients across the globe and providing a positive impact on patient lives. Our clinical development program is investigating new chemical entities and biologics to treat cardiovascular disease, metabolic disease, cancer and diseases in other therapeutic areas.

Founded in 2007, Genor Biopharma Co. Ltd (Genor BioPharma, Stock code: 6998.HK) is an innovation-driven biopharma company with a pipeline of therapies covering the world's top oncology areas (breast, lung, and gastrointestinal cancer).

科兴制药是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业，专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发，并围绕上述治疗领域拥有一定中药及化学药技术沉淀。 科兴制药主要产品包括重组蛋白药物"重组人促红素"、"重组人干扰素α1b"、"重组人粒细胞刺激因子"，微生态制剂药物"酪酸梭菌二联活菌"。公司主要产品已沉淀一定行业优势地位和市场影响力，近年来依托政策支持和营销渠道深耕，保持稳定增长。

Qilu Pharmaceuticals is a leading Chinese pharmaceutical company founded in 1958, recognized as one of the top three players in China's pharmaceutical industry. The company operates as a vertically integrated enterprise, focusing on human medicines, veterinary medicines, and crop protection products. It has 12 subsidiaries and 11 manufacturing sites across China. Qilu's product portfolio includes over 300 finished dosage forms, making it a prominent manufacturer of injectables and solid-dose medications. The company also produces a wide range of active pharmaceutical ingredients (APIs) and has a robust pipeline with more than 200 generic drugs, 20–30 biosimilars, and 80–90 innovative drugs in development. With a global reach, Qilu exports products to over 100 countries and has established subsidiaries in the U.S., Europe, and Brazil. The company employs over 39,000 people worldwide, with a strong emphasis on affordable medicines and improving global health.

Mainly supplying the international API market, ScinoPharm has become one of the leading international oncology generic APIs suppliers (in terms of generic APIs supply). In addition to anti-cancer APIs, we have also developed a wide variety of other products including CNS APIs, gastrointestinal APIs, etc.

Shanghai Henlius Biotech isabiopharmaceutical company in China that is developing biologics foroncology and autoimmune diseases.

亿帆医药股份有限公司是一家在深圳交易所A股上市的企业，证券简称：亿帆医药，证券代码：002019。 公司为医药创新型研发生产企业，设有亿帆研究院、国家级博士后科研工作站、省级企业技术中心（研发中心），旗下拥有多家高新技术企业，现有药学及相关专业硕士、博士逾百名，拥有双分子技术、免疫抗体技术两大先进生物药创新研发平台，已获国际及国内药品相关专利授权近百项，其中国际专利35项。 公司承担了国家"十五"攻关项目、国家高技术产业化示范工程项目、国家火炬计划项目等，曾荣获国家发明二等奖、国家科技进步二等奖各一项。 公司以专业性、专科性及治疗型重点专科领域产品线为导向，不断创新，转型升级，向大分子生物药、高端化药及特色中药等重点领域发展。拥有几十个在研高端化药，其中近10个已处临床或报产阶段；拥有妇科、儿科、皮肤科等药品批准文号400余个，其中独家特色中西药40多个，独家医保品种20余个。现有数个正处国际临床II期、III期的大分子生物药，是第一家大分子创新生物药在美国进入II期、III期临床试验的中国企业，将带领中国生物药叩响美国的大门。 公司已形成以安徽为主的小分子高端化药、植物药生产中心，以四川为主的皮肤科、妇科生产中心，以辽宁为主的骨科、治疗型大输液生产中心，以北京、上海为主的大分子生物药研发与生产中心及以浙江为主的原料药生产中心。 公司医药业务覆盖除港澳台以外的所有省市区，药品制剂在全国二级以上医院的覆盖率超过60%，同时作为世界较大的维生素B5及维生素原B5生产供应商，公司医用原料药销售网络辐射欧、美等多个国家和地区，全球市场占有率40%-45%，稳居龙头地位。 面向未来，公司将始终专注于医药、医疗健康事业，坚持"整合、创新、国际化"的发展战略，恪守"务实、创新、诚信、勤奋"的核心价值观，致力于为客户创造效益，为员工创造平台，为股东创造财富，为社会创造价值，持续成长为全球医药健康事业的专家。